Mantle Cell Lymphoma disease: Malacards - Research Articles, Symptoms, Drugs, Genes, Clinical Trials

Summaries for Mantle Cell Lymphoma

Sources:
⁹Disease Ontology, ⁴²NIH Rare Diseases, ⁶⁴Wikipedia, ³²MalaCards
See all sources

NIH Rare Diseases:⁴² Mantle cell lymphoma (mcl) belongs to a group of diseases known as non-hodgkin’s lymphomas (nhl), which are cancers that affect the the lymphatic system (part of the immune system). mcl accounts for 6% of all non-hodgkin lymphomas and is mostly found in males during their early 60s. lymphocytes, which are white blood cells that make up the lymphatic system. there are two main types: b-lymphocytes (b-cells) and t-lymphocytes (t-cells). mantel cell lymphoma is a b-cell lymphoma that develops from cancerous b-cells within a region of the lymph node known as the mantle zone. although mantle cell lymphomas are slow-growing cancers, at the time of diagnosis, they are usually widespread in the lymph nodes and require intensive treatment because they can become lethal within a short period of time. last updated: 7/20/2011

MalaCards based summary: Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to chronic lymphocytic leukemia and macroglobulinemia, and has symptoms including lymphadenopathy, hematological neoplasm and splenomegaly. An important gene associated with Mantle Cell Lymphoma is ATM (ataxia telangiectasia mutated), and among its related pathways are TP53 network and FOXM1 transcription factor network. The compounds okadaic acid and tyrosine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and lymph node, and related mouse phenotypes are tumorigenesis and hematopoietic system.

Disease Ontology:⁹ A b-cell lymphocytic neoplasm due to cd5 positive antigen-naive pregerminal center b-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia:⁶⁴ Mantle cell lymphoma (MCL) is one of the rarest of the non-Hodgkin\'s lymphomas (NHLs), comprising about... more...

Aliases & Classifications for Mantle Cell Lymphoma

Sources:
³¹LifeMap Discovery®, ⁹Disease Ontology, ⁴²NIH Rare Diseases, ¹¹DISEASES, ⁴⁸Orphanet, ⁶¹UMLS, ²³GTR, ⁴⁶OMIM, ⁴⁴Novoseek, ³⁵MESH via Orphanet, ²⁷ICD10 via Orphanet, ²⁶ICD10
See all sources

Mantle Cell Lymphoma, Aliases & Descriptions:

Name: Mantle Cell Lymphoma ³¹ ⁹ ⁴² ¹¹ ⁴⁸

Lymphoma, Mantle Cell ⁴² ²³ ⁴⁶

Lcm ⁴⁸ ⁶¹

Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse ⁶¹

Malignant Lymphoma - Lymphocytic, Intermediate Differentiation ⁶¹

Mantle Zone Lymphoma ⁴⁸

Lymphoma Mantle-Cell ⁴⁴

Mcl ⁴⁸

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Rare diseases, Cancer diseases
Anatomical: Blood diseases, Immune diseases

ICD10: ²⁷ ²⁶

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Non-follicular lymphoma

Mantle cell lymphoma

Orphanet: ⁴⁸

Rare haematological diseases

Rare tumors

Characteristics (Orphanet epidemiological data):

⁴⁸

mantle cell lymphoma:
Inheritance: Multigenic/multifactorial,Sporadic; Prevalence: 1-9/100000; Age of onset: Adulthood; Age of death: Adult

External Ids:

Disease Ontology⁹ DOID:0050746

MESH via Orphanet³⁵ D020522

ICD10 via Orphanet²⁷ C83.1

ICD10²⁶ C83.1

Related Diseases for Mantle Cell Lymphoma

Sources:
¹⁸GeneCards, ¹⁹GeneDecks
See all sources

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50) (show all 101)

id	Related Disease	Score	Top Affiliating Genes
1	chronic lymphocytic leukemia	31.3	ATM, IGH, IGHM, CCND1, CD5
2	macroglobulinemia	31.3	CD5
3	multiple myeloma	31.2	CCND1, CCND2, CKS1B
4	myeloma	31.1	IGH, IGHM, CCND1, CCND2
5	b-cell lymphomas	31.1	ATM, IGH, IGHM, CCND1, CCND2, CD5
6	hodgkin's lymphoma	31.1	ATM, IGH, IGHM, CCND2
7	leukemia	31.0	ATM, IGH, PRAME, CCND1, CCND2, CD5
8	non-hodgkin lymphoma	30.9	ATM, IGH, CCND1, CCND2, CD5, CD52
9	prolymphocytic leukemia	30.9	ATM, CCND1, CD5
10	malt lymphoma	30.9	CD5, CCND1, IGHM, IGH
11	follicular lymphoma	30.9	IGH, IGHM, CCND1, CD5
12	hairy cell leukemia	30.9	CCND1, CD5
13	burkitt's lymphoma	30.6	ATM, CCND1
14	acute leukemia	30.3	PRAME, IGH, ATM
15	adenoma	30.2	ATM, CCND1, CCND2, CKS1B
16	diffuse large b-cell lymphoma	10.7
17	marginal zone b-cell lymphoma	10.5
18	prostatitis	10.5
19	splenomegaly	10.5
20	cryoglobulinemia	10.4	CD5
21	glomerulonephritis	10.4
22	hematopoietic stem cell transplantation	10.4
23	splenic marginal zone lymphoma	10.4
24	endotheliitis	10.4
25	macroglobulinemia, waldenstrom, somatic	10.4	CCND1, IGHM, IGH
26	cryoglobulinemic vasculitis	10.4	IGHM, CD5
27	ataxia telangiectasia	10.3
28	peripheral t-cell lymphoma	10.3
29	thrombocytopenia	10.3
30	membranoproliferative glomerulonephritis	10.3
31	leukostasis	10.3
32	composite lymphoma	10.3
33	gastrointestinal stromal tumor	10.3
34	adenocarcinoma	10.3
35	interstitial nephritis	10.3
36	pancreatitis	10.3
37	ataxia	10.3
38	nephritis	10.3
39	wells syndrome	10.3
40	malignant glioma	10.2	SOX11, CCND1, CCND2
41	breast cancer, invasive ductal	10.2	ATM, CCND1
42	acute myeloid leukemia	10.2
43	anaplastic large cell lymphoma	10.2
44	focal segmental glomerulosclerosis	10.2
45	hepatitis	10.2
46	lymphoblastic lymphoma	10.2
47	myasthenia gravis	10.2
48	myelofibrosis	10.2
49	neutropenia	10.2
50	prostate cancer	10.2

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:

Symptoms for Mantle Cell Lymphoma

Sources:
⁵⁸The Human Phenotype Ontology, ⁴⁸Orphanet
See all sources

Symptoms:

⁴⁸ (show all 7)

lymphadenopathy/polyadenopathies
hematologic/blood/lymphatic cancer
splenomegaly
anorexia

bone marrow/medullar infiltration
weight loss/loss of appetite/break in weight curve/general health alteration
asthenia/fatigue/weakness

HPO human phenotypes related to Mantle Cell Lymphoma:

id	Description	Frequency	HPO Source Accession
1	lymphadenopathy	hallmark (90%)	HP:0002716
2	hematological neoplasm	hallmark (90%)	HP:0004377
3	splenomegaly	typical (50%)	HP:0001744
4	weight loss	typical (50%)	HP:0001824
5	anorexia	typical (50%)	HP:0002039

Drugs & Therapeutics for Mantle Cell Lymphoma

Sources:
⁴¹NIH Clinical Center, ⁶ClinicalTrials, ³¹LifeMap Discovery®, ⁶¹UMLS, ⁴⁰NDF-RT
See all sources

Drug clinical trials:

Search ClinicalTrials for Mantle Cell Lymphoma

Search NIH Clinical Center for Mantle Cell Lymphoma

Cell-based therapeutics:

The database of embryonic development, stem cell research and regenerative medicine

Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Mantle Cell Lymphoma:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
	Peripheral blood stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Mantle Cell Lymphoma:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Peripheral blood-derived hematopoietic stem cells, PMID: 21831743
	Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Mantle Cell Lymphoma

Sources:
²³GTR
See all sources

Genetic tests related to Mantle Cell Lymphoma:

id	Genetic test	Affiliating Genes
1	Mantle Cell Lymphoma²³

Anatomical Context for Mantle Cell Lymphoma

Sources:
³²MalaCards
See all sources

MalaCards organs/tissues related to Mantle Cell Lymphoma:

³²

B cells, T cells, Lymph node, Bone, Bone marrow, Colon, Prostate, Monocytes, Skin, Endothelial, Testis, Brain, Small intestine, Kidney, Adrenal gland, Breast, Testes, Myeloid, Trachea, Appendix

Animal Models for Mantle Cell Lymphoma or affiliated genes

Sources:
³⁶MGI
See all sources

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

³⁶

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	tumorigenesis	MP:0002006	9.5	CKS1B, CCND1, PMAIP1, IGHM, ATM
2	hematopoietic system phenotype	MP:0005397	8.5	CCND2, CKS1B, CCND1, SOX11, PMAIP1, IGL
3	immune system phenotype	MP:0005387	8.3	CD5, ATM, CKS1B, CCND2, CCND1, SOX11

Publications for Mantle Cell Lymphoma

Sources:
⁵¹PubMed
See all sources

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 840)

id	Title	Authors	Year
1	Ibrutinib approved for mantle cell lymphoma. (24402946)		2014
2	Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. (23730878)	Zhang L.... Wang M.	2013
3	Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. (24030098)	Zinzani P.L.... Witzig T.E.	2013
4	Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus. (23137523)	Schilling G.... Dierlamm J.	2013
5	MicroRNAs in mantle cell lymphoma. (23339447)	Husby S.... nbA	2013
6	Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. (23940282)	Chang B.Y.... Elias L.	2013
7	A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. (24107828)	Kanduri M.... Rosenquist R.	2013
8	Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. (23772666)	Salek D.... TrnA9nA1 M.	2013
9	Current and emerging therapies in mantle cell lymphoma. (23512567)	Brett L.K.... Williams M.E.	2013
10	Mantle cell lymphoma presenting as a pelvi-ureteric junction obstruction: a case report. (23590763)	Naranji I.... Liston T.	2013
11	Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. (22475365)	Shi W.... Shi Y.	2012
12	Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? (22550404)	Kirschey S.... Hess G.	2012
13	NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. (22920938)	Civallero M.... Sacchi S.	2012
14	FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? (22377620)	Alinari L.... Praetorius-Ibba M.	2012
15	Scoring systems in mantle cell lymphoma: a critical point of view. (21915995)	JuncA J.... MillA! F.	2012
16	A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. (22185662)	Warsch S.... Lossos I.S.	2012
17	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. (21067447)	Yi J.H.... Kim W.S.	2011
18	Chlorambucil in indolent mantle cell lymphoma--just another old drug for a new disease? (21271863)	Dreyling M.... Tadmor T.	2011
19	Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. (21750224)	Dasmahapatra G.... Grant S.	2011
20	Prognostic relevance of clinical risk factors in mantle cell lymphoma. (21782060)	Hoster E.	2011
21	Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. (21509767)	Dietrich S.... Dreger P.	2011
22	Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. (21850989)	Sander B.	2011
23	Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. (21609366)	Kimura Y.... Ohshima K.	2011
24	Utility of positron emission tomography scans in mantle cell lymphoma. (21922524)	Hosein P.J.... Lossos I.S.	2011
25	Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. (21067446)	Galimberti S.... Petrini M.	2011
26	Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. (21603610)	Enjuanes A.... Jares P.	2011
27	Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. (21712452)	Weniger M.A.... Wiestner A.	2011
28	Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. (20558579)	MartA-n-PAcrez D.... SA!nchez-Beato M.	2010
29	Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. (20647473)	Rao R.... Bhalla K.N.	2010
30	CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report. (18572329)	Yoo S.B.... Kim C.W.	2008
31	Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. (17606765)	Kawamata N.... Koeffler H.P.	2007
32	Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. (17136116)	Haritunians T.... Koeffler H.P.	2007
33	Successful treatment of focal segmental glomerulosclerosis in association with mantle cell lymphoma. (17497453)	Wong C.F.... Rustom R.	2007
34	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. (16461462)	Greiner T.C.... Hacia J.G.	2006
35	Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. (16645163)	Rudelius M.... Raffeld M.	2006
36	Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. (16155021)	FernA ndez V.... Rosenwald A.	2005
37	Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. (16337199)	Flygare J.... Sander B.	2005
38	Biology and therapy of mantle cell lymphoma. (16093790)	Williams M.E.... Densmore J.J.	2005
39	Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. (16219581)	Hipp S.... Decker T.	2005
40	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. (16123218)	Fu K.... Chan W.C.	2005
41	Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. (14630827)	Thieblemont C.... Houlgatte R.	2004
42	PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas. (11342371)	Zhu Y.... Knuutila S.	2001
43	Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. (10942246)	Visser H.P.... Kluin-Nelemans J.C.	2000
44	Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. (11035575)	Izban K.F.... Hsi E.D.	2000
45	Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome. (11193469)	Molina T.J.... Diebold J.	2000
46	Quantitative RNA slot-blot analysis of CCND1/cyclin D1 expression in suspected mantle cell lymphoma. (9436924)	Mauvieux L.... Macintyre E.A.	1998
47	Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. (9209645)	Williams M.E.... Swerdlow S.H.	1997
48	Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. (8623927)	Jares P.... Cardesa A.	1996
49	Detection of bcl-1 gene rearrangement and B-cell clonality in mantle cell lymphoma using formalin-fixed, paraffin-embedded tissues. (8526214)	Lim L.C.... Wittwer C.T.	1995
50	Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. (7595744)	Teodorovic I.... Peeters C.D.	1995

Genes related to Mantle Cell Lymphoma

Sources:
¹⁸GeneCards, ¹antibodies-online, ⁴⁵Novus Biologicals, ⁴⁶OMIM, ⁴⁸Orphanet
See all sources

Genes related to Mantle Cell Lymphoma:

(show all 27)

- Elite gene

id	Symbol	Description	Score	Implication
1	ATM	ataxia telangiectasia mutated	20.36	Molecular basis known ⁴⁶ Causative somatic mutation ⁴⁸ GeneCards inferred via : Publications, Disorders, Functions (show sections)
2	CCND1	cyclin D1	19.62	Causative somatic mutation ⁴⁸ GeneCards inferred via : Publications, Functions (show sections)
3	IGH	immunoglobulin heavy locus	18.88	Causative somatic mutation ⁴⁸ GeneCards inferred via : Publications (show sections)
4	MIR17	microRNA 17	18.14	GeneCards inferred via : Publications (show sections)
5	MIR17HG	miR-17-92 cluster host gene (non-protein coding)	17.40	GeneCards inferred via : Publications (show sections)
6	MIR16-1	microRNA 16-1	16.66	GeneCards inferred via : Publications (show sections)
7	PMAIP1	phorbol-12-myristate-13-acetate-induced protein 1	15.92	GeneCards inferred via : Publications (show sections)
8	IGHM	immunoglobulin heavy constant mu	15.17	GeneCards inferred via : Publications (show sections)
9	CD5	CD5 molecule	14.43	GeneCards inferred via : Publications (show sections)
10	SOX11	SRY (sex determining region Y)-box 11	13.69	GeneCards inferred via : Publications, Disorders (show sections)
11	IGL	immunoglobulin lambda locus	12.95	GeneCards inferred via : Publications (show sections)
12	MIR20A	microRNA 20a	12.21	GeneCards inferred via : Publications (show sections)
13	NTN3	netrin 3	11.47	GeneCards inferred via : Publications (show sections)
14	HILPDA	hypoxia inducible lipid droplet-associated	10.73	GeneCards inferred via : Publications (show sections)
15	MIR29A	microRNA 29a	9.99	GeneCards inferred via : Publications (show sections)
16	CD52	CD52 molecule	9.25	GeneCards inferred via : Publications (show sections)
17	CKS1B	CDC28 protein kinase regulatory subunit 1B	8.51	GeneCards inferred via : Publications (show sections)
18	CCND2	cyclin D2	7.77	GeneCards inferred via : Publications (show sections)
19	CDK20	cyclin-dependent kinase 20	7.03	GeneCards inferred via : Publications (show sections)
20	PRAME	preferentially expressed antigen in melanoma	6.29	GeneCards inferred via : Publications (show sections)
21	CD70	CD70 molecule	5.55	GeneCards inferred via : Publications (show sections)
22	DEGS1	delta(4)-desaturase, sphingolipid 1	4.80	GeneCards inferred via : Publications (show sections)
23	HIC1	hypermethylated in cancer 1	4.06	GeneCards inferred via : Publications (show sections)
24	PIM2	pim-2 oncogene	3.32	GeneCards inferred via : Publications (show sections)
25	RGS13	regulator of G-protein signaling 13	2.58	GeneCards inferred via : Publications (show sections)
26	WNT10A	wingless-type MMTV integration site family, member 10A	1.84	GeneCards inferred via : Publications (show sections)
27	CCNG1	cyclin G1	1.10	GeneCards inferred via : Publications (show sections)

Products for genes related to Mantle Cell Lymphoma disease:

id	Company	Proteins	Lysates	Antibodies	Kits and Assays
1	Antibodies-online	19	-	21	21
2	Novus Biologicals	17	17	22	-

Variations for Mantle Cell Lymphoma

Expression for genes affiliated with Mantle Cell Lymphoma

Sources:
²BioGPS, ¹⁶Gene Expression Omnibus DataSets
See all sources

Expression patterns in normal tissues for genes affiliated with Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for genes affiliated with Mantle Cell Lymphoma

Sources:
⁴⁹PathCards, ³⁷NCBI BioSystems Database, ⁵⁴Reactome, ⁵²QIAGEN, ⁵⁹Thomson Reuters, ⁵³R&D Systems, ³⁰KEGG, ⁵⁵SinoBiological, ⁵Cell Signaling Technology, ¹³EMD Millipore
See all sources

Pathways related to Mantle Cell Lymphoma according to GeneCards/GeneDecks:

(show all 28)

id	Super pathways (with members indented)	Score	Top Affiliating Genes
1	TP53 network³⁷ Show member pathways Activation, translocation and oligomerization of BAX⁵⁴	10.2	PMAIP1, ATM
2	FOXM1 transcription factor network³⁷	10.0	CKS1B, CCND1
3	Ovarian Infertility Genes³⁷	10.0	CCND2, ATM
4	IL-10 Pathway⁵²	10.0	CCND1, CCND2
5	Development Angiotensin activation of ERK⁵⁹ Show member pathways Development EDNRB signaling⁵⁹ Development ACM2 and ACM4 activation of ERK⁵⁹ Cell adhesion Integrin inside out signaling⁵⁹ Development G Proteins mediated regulation MARK ERK signaling⁵⁹ Signal transduction IP3 signaling⁵⁹ Development Angiotensin signaling via PYK2⁵⁹ Development EPO induced MAPK pathway⁵⁹	9.9	IGL, IGHM, IGH
6	Immune response Fc epsilon RI pathway⁵⁹ Show member pathways VEGF - VEGF R2 Signaling Pathways⁵³ VEGF signaling pathway³⁰ Immune response BCR pathway⁵⁹ Fc epsilon RI signaling pathway³⁰ Fc-epsilon receptor I signaling in mast cells³⁷	9.9	IGH, IGHM, IGL
7	Immune response NFAT in immune response⁵⁹ Show member pathways Immune response T cell receptor signaling pathway⁵⁹ Immune response CD28 signaling⁵⁹ Immune response ICOS pathway in T helper cell⁵⁹	9.9	IGH, IGHM, IGL
8	Complement Pathway⁵² Show member pathways Immune response Alternative complement pathway⁵⁹ Classical Complement Pathway⁵² Terminal pathway of complement⁵⁴ Complement Activation Pathways⁵⁵ Regulation of Complement cascade⁵⁴ Immune response Lectin Induced complement pathway⁵⁹ Activation of C3 and C5⁵⁴ Immune response Classic complement pathway⁵⁹ Lectin Induced Complement Pathway⁵² Alternative Complement Pathway⁵²	9.9	IGL, IGHM, IGH
9	Cell Cycle / Checkpoint Control⁵ Show member pathways DNA Damage⁵	9.9	CCND2, CCND1, ATM
10	FoxO signaling pathway³⁰ Show member pathways PLK2 and PLK4 events³⁷ Polo-like kinase signaling events in the cell cycle³⁷	9.9	ATM, CCND1, CCND2
11	Glioma³⁰ Show member pathways Melanoma³⁰ Non-small cell lung cancer³⁰ Bladder cancer³⁰ Prostate cancer³⁰ Signaling Pathways in Glioblastoma³⁷	9.9	CCND2, CCND1, ATM
12	Cell cycle³⁰ Show member pathways Cell cycle³⁷	9.9	CCND2, CCND1, ATM
13	GADD45 Pathway⁵²	9.9	CCND2, CCND1, ATM
14	DNA damage ATM ATR regulation of G1 S checkpoint⁵⁹	9.9	ATM, CCND1, CCND2
15	Viral carcinogenesis³⁰	9.8	CCND2, CCND1, PMAIP1
16	B Cell Receptor Signaling Pathway³⁷	9.8	CD5, CCND2, IGHM
17	Cell cycle Regulation of G1 S transition part 2 ⁵⁹ Show member pathways G2 Phase⁵⁴ Cell cycle ESR1 regulation of G1 S transition⁵⁹ Immune response MIF JAB1 signaling⁵⁹ Cell cycle Cell cycle generic schema ⁵⁹	9.7	CCND1, CCND2, CKS1B
18	Cell cycle Regulation of G1 S transition part 1 ⁵⁹ Show member pathways Cell cycle Role of SCF complex in cell cycle regulation⁵⁹	9.7	CKS1B, CCND2, CCND1
19	CDK-mediated phosphorylation and removal of Cdc6⁵⁴ Show member pathways APC/C-mediated degradation of cell cycle proteins⁵⁴ Antigen processing-Cross presentation⁵⁴ Autodegradation of the E3 ubiquitin ligase COP1⁵⁴ Destabilization of mRNA by Butyrate Response Factor 1 (BRF1)⁵⁴ SCF-beta-TrCP mediated degradation of Emi1⁵⁴ Regulation of Apoptosis⁵⁴ Regulation of PAK-2p34 activity by PS-GAP/RHG10⁵⁴ Destabilization of mRNA by KSRP⁵⁴ DNA Replication Pre-Initiation⁵⁴ Cross-presentation of particulate exogenous antigens (phagosomes)⁵⁴ Switching of origins to a post-replicative state⁵⁴ Proteasome Degradation³⁷ Regulation of mRNA Stability by Proteins that Bind AU-rich Elements⁵⁴ M/G1 Transition⁵⁴ Conversion from APC/C-Cdc20 to APC/C-Cdh1 in late anaphase⁵⁴ CDC6 association with the ORC-origin complex⁵⁴ S Phase⁵⁴ Degradation of beta-catenin by the destruction complex⁵⁴ Immune response Antigen presentation by MHC class I⁵⁹ Phosphorylation of the APC/C⁵⁴ Regulation of mitotic cell cycle⁵⁴ Cyclin A-Cdk2-associated events at S phase entry⁵⁴ Regulation of APC/C activators between G1/S and early anaphase⁵⁴ APC/C-Cdc20 mediated degradation of mitotic proteins⁵⁴ Proteasome³⁰ Association of licensing factors with the pre-replicative complex⁵⁴ ER-Phagosome pathway⁵⁴ CDT1 association with the CDC6-ORC-origin complex⁵⁴ Cell Cycle Checkpoints⁵⁴ Cyclin E associated events during G1/S transition⁵⁴ Beta-catenin phosphorylation cascade⁵⁴ Parkinson's Disease Pathway⁵² APC/C-Cdh1 mediated degradation of Cdc20 and other APC/C-Cdh1 targeted proteins in late mitosis/early G1⁵⁴ APC/C-Cdc20 mediated degradation of Securin⁵⁴ Activation of APC/C and APC/C-Cdc20 mediated degradation of mitotic proteins⁵⁴ Activation of NF-kappaB in B Cells⁵⁴ Vpu mediated degradation of CD4⁵⁴ Regulation of activated PAK-2p34 by proteasome mediated degradation⁵⁴ p53-Independent G1/S DNA damage checkpoint⁵⁴ Regulation of ornithine decarboxylase (ODC)⁵⁴ Stabilization of mRNA by HuR⁵⁴ WNT5A-dependent internalization of FZD4⁵⁴ Destabilization of mRNA by Tristetraprolin (TTP)⁵⁴ SCF(Skp2)-mediated degradation of p27/p21⁵⁴ Regulation of DNA replication⁵⁴ Role of DCC in regulating apoptosis⁵⁴ Ubiquitin-dependent degradation of Cyclin D⁵⁴ Ubiquitin Mediated Degradation of Phosphorylated Cdc25A⁵⁴ p53-Dependent G1/S DNA damage checkpoint⁵⁴ p53-Dependent G1 DNA Damage Response⁵⁴ Apoptosis⁵⁴ DNA Replication⁵⁴ Vif-mediated degradation of APOBEC3G⁵⁴ Destabilization of mRNA by AUF1 (hnRNP D0)⁵⁴ p53-Independent DNA Damage Response⁵⁴ Cross-presentation of soluble exogenous antigens (endosomes)⁵⁴ Removal of licensing factors from origins⁵⁴ Endosomal/Vacuolar pathway⁵⁴ Stabilization of p53⁵⁴ Assembly of the pre-replicative complex⁵⁴ Ubiquitin-dependent degradation of Cyclin D1⁵⁴ PCP/CE pathway⁵⁴ G1/S DNA Damage Checkpoints⁵⁴ Orc1 removal from chromatin⁵⁴ Asymmetric localization of PCP proteins⁵⁴ Autodegradation of Cdh1 by Cdh1-APC/C⁵⁴ Establishment of Sister Chromatid Cohesion⁵⁴ WNT5A-dependent internalization of FZD2, FZD5 and ROR2⁵⁴ Synthesis of DNA⁵⁴	9.7	ATM, PMAIP1, CCND1, CKS1B
20	p53 signaling pathway³⁰ Show member pathways DNA damage response³⁷	9.7	CCND2, CCND1, PMAIP1, ATM
21	Wnt Signaling Pathway³⁷ Show member pathways DNA damage response (only ATM dependent)³⁷ Wnt Signaling Pathway and Pluripotency³⁷	9.7	CCND2, CCND1, PMAIP1, ATM
22	Development IGF 1 receptor signaling⁵⁹ Show member pathways Development IGF RI signaling¹³ Immune response IL 4 signaling pathway⁵⁹ Signal transduction AKT signaling⁵⁹	9.7	IGH, IGL, CCND1, CCND2
23	Cyclins and Cell Cycle Regulation⁵² Show member pathways Cell Cycle Control by BTG Proteins⁵² Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes⁵⁴ G1-S Phase Transition⁵² G1 Phase⁵⁴ Cyclin D associated events in G1⁵⁴	9.6	ATM, CCND1, CCND2, CKS1B
24	Cell Cycle, Mitotic⁵⁴ Show member pathways Cell Cycle⁵⁴ M Phase⁵⁴	9.6	ATM, CCND1, CCND2, CKS1B
25	E2F mediated regulation of DNA replication⁵⁴ Show member pathways E2F-enabled inhibition of pre-replication complex formation⁵⁴ G1/S-Specific Transcription⁵⁴ G1 to S cell cycle control³⁷ G1/S Transition⁵⁴ Mitotic G1-G1/S phases⁵⁴ Inhibition of replication initiation of damaged DNA by RB1/E2F1⁵⁴ Assembly of the ORC complex at the origin of replication⁵⁴	9.6	ATM, CCND1, CCND2, CKS1B
26	ERK Signaling⁵² Show member pathways ILK Signaling⁵² Molecular Mechanisms of Cancer⁵² Rho Family GTPases⁵² MAPK Signaling⁵²	9.5	ATM, PMAIP1, SOX11, CCND1, CCND2
27	miRNAs involved in DDR³⁷	9.4	MIR29A, MIR17, MIR20A, MIR16-1, CCND1, ATM
28	MicroRNAs in cancer³⁰	9.1	ATM, CCND1, CCND2, MIR16-1, MIR20A, MIR17

Compounds for genes affiliated with Mantle Cell Lymphoma

Sources:
⁴⁴Novoseek, ⁶⁰Tocris Bioscience
See all sources

Compounds related to Mantle Cell Lymphoma according to GeneCards/GeneDecks:

id	Compound	Score	Top Affiliating Genes
1	okadaic acid⁴⁴ ⁶⁰	10.9	CDK20, CCND1, ATM
2	tyrosine⁴⁴	8.8	CD5, CDK20, CKS1B, CCND2, CCND1, ATM

GO Terms for genes affiliated with Mantle Cell Lymphoma

Sources:
¹⁷Gene Ontology
See all sources

Cellular components related to Mantle Cell Lymphoma according to GeneCards/GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	cyclin-dependent protein kinase holoenzyme complex	GO:000307	10.0	CCND2, CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards/GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	response to X-ray	GO:010165	10.1	CCND1, PMAIP1
2	positive regulation of cyclin-dependent protein kinase activity	GO:045737	9.9	CCND1, CCND2
3	positive regulation of DNA damage response, signal transduction by p53 class mediator	GO:043517	9.9	PMAIP1, ATM
4	cell division	GO:051301	9.4	CDK20, CKS1B, CCND2, CCND1